5×GRE XhoI-SacI fragment from pG5E1bLuc and replacing it with a shortened version of the excised fragment. This insert was generated by annealing of oligos, followed by Klenow fill-in and finally digestion by XhoI and SacI. The pGL3b-5GRE-SNRPN is an SNRPN-driven Gal4p-responsive luciferase reporter, which has been described earlier (2) .
Mammalian expression plasmids. The mammalian expression vectors pCIneo-hcM-HA and pCIneo-hcM-HA-2KR (encoding wild-type and sumoylation deficient c-Myb, respectively), pCIneo-hcM-HA-K503R and pCIneo-hcM-HA-K527R (single sumoylation sites mutated) have been described (3) . c-Myb mutants pCIneoB-hcM-HA-E505A, pCIneoB-hcM-HA-E529A and pCIneoB-hcM-HA-E505/529R (abbreviated 2EA) were generated using the Quick Change Site-Directed Mutagenesis Kit (Stratagene) on a subfragment of human MYB, before subcloned into pCIneoB-hcM-HA. pCIneo-hcM-2KR-SUMO-1 was constructed by PCR amplification and modification of SUMO-1 from the appropriate IMAGE clone, followed by subcloning in-frame into pCIneo-hcM-HA-2KR (between PshAI and SalI), loosing the HA tag, but gaining SUMO-1 in the expressed product. pCIneo-hcM-VP16 was made by PCR amplification of the herpes simplex virus VP16 transactivation domain from pDBD11 (4). The VP16-TAD region was subcloned in-frame into pCIneo-hcM. pCIneo-hcM-VP16-2KR has been described (2).
The expression plasmids pEF1neo-3FLAG-hcM-HA and pEF1neo-3FLAG-hcM-HA-2KR, used for stable integration into K562 cells, were made by exchanging the CMV promoter in pCIneo with the human EEF1A1 promoter (source: the pEBB vector). The region encoding three consecutive FLAG tags was from pCIneoB-3FLAG (2), and the cDNAs encoding hcM-HA or hcM-2KR-HA were subcloned from their corresponding pCIneo constructs. pCIneo-AMV encoding the AMV v-Myb protein (residue 72-440 in chicken c-Myb) is described in (5), while the pCIneo-hcM-∆NRD-HA, encoding human c-Myb residue 1-443, has been described elsewhere (6) .
The c-Myb expression constructs with the central TAD deleted (pCIneoB-hcM-ΔT1-HA and pCIneoB-hcM-ΔT1-HA-2KR) were made from a cDNA in Bluescript lacking an internal fragment (HpaI to SmaI) encoding human c-Myb amino acids 229-325. The EcoRI-BglII fragment from pBS-ΔSE-hcM-ΔT1 was subcloned between the corresponding sites in pCIneoB-hcM-HA and pCIneoB-hcM-HA-2KR, respectively.
The mammalian expression vectors for Gal4p-DBD fused to HA-tagged human c-Myb NRD (pCIneoB-GBD2-NRD-HA; coding for amino acid residue 410 to 640) were made by PCR amplification of the corresponding sequence in pCIneo-hcM-HA and subcloning of this 3 fragment into pCIneoB-GBD2 (described earlier (2)) between SalI and NotI. pCIneoB-GBD2-NRD-HA-2KR and -2EA were made by subcloning the BglII-NotI fragment from pCIneohcM-HA-2KR and -2EA, respectively, into pCIneoB-GBD2-NRD-HA. The Gal4p-DBD NRD-SUMO fusion proteins were made by the same strategy using pCIneo-hcM-2KR-SUMO-1 and pCIneo-hcM-SUMO-1 (2). The GBD-TAD fusion construct, covering amino acid residues 259 to 337 from human c-Myb, were made by PCR amplification using pCIneo-hcM-HA as template and subcloning the fragment into pCIneoB-GBD2 between SalI and NotI. The same strategy was used for the pCIneo-GBD2-p53-CRD expression vector (encoding amino acid residue 300 to 393 of human p53) as well as for the sumoylation deficient pCIneo-GBD2-p53- respectively. pCIneoB-3FLAG-Mi2α, expressing full-length FLAG-tagged Mi-2α, has been described (2).
pSG424-Sp3 and pSG424-Sp3/kee (mutated I 550 KEE -> I 550 AAA), both encoding human Sp3 amino acid residue 81-613 (acc.no. NP_003102) in fusion with Gal4p DBD (7), were kind gifts from Prof. G. Suske. pCIneoB-GBD2-Sp3-ID-HA and pCIneoB-GBD2-Sp3-ID-HA/kee encoding the inhibitory domain of Sp3 (ID; amino acid residue 534-612) in fusion with Gal4p DBD, were made by PCR amplification of the corresponding cDNA from the pSG424-Sp3 constructs.
The SENP1 expression plasmids pFlag-CMV-SENP1 and pFlag-CMV-SENP1-mutant (R630L, K631M) were a kind gift from Dr. E.T. Yeh (8) . The p300 expressing mammalian vector pCMVβ-NHA-p300 was a kind gift from Prof. D. Livingston and has been described previously (9) . pCMV-T7-mPIASy (10) expressing PIASy was kindly provided by Prof. R.
Grosschedl.

Electrophoretic Mobility Shift Assay (EMSA)
Expression of Myb proteins for EMSA. The human c-Myb DNA-binding domain, covering
Myb repeats 1-3 ("R123"; amino acid residues 38-192) was expressed in E. coli and purified as earlier described (11) (12) (13) (14) . The lysates were then centrifuged for 30 min at 4 °C, before aliquots of the supernatant were frozen in liquid N 2 and stored at -80 °C.
EMSA. DNA binding was monitored by EMSA as previously described (12 
Supplementary results
Synergy control is not caused by weakening of the DNA-binding by SUMO.
To monitor DNA-binding properties we expressed the three Myb variants: c-Myb wild-type, cMyb 2KR, and c-Myb-2KR-SUMO1 in COS-1 cells. We evaluated the amount of protein by
Western analysis (Fig. S1 , middle and lower panel) and performed EMSA. With equal input of c-Myb proteins, the specific DNA-binding observed was similar for c-Myb wild-type and 2KR, as well as for the SUMO-fusion protein (Fig. S1 upper panel) , suggesting that SUMO moieties conjugated ( Fig. S1; lower panel) 
c-Myb-dependent activation of the MYC promoter is highly SUMO-dependent.
To examine how SUMO-modification influenced the c-Myb responsiveness of the MYC promoter (analyzed by ChIP in Fig. 4) , we tested the same MYC promoter region in a reporter assay and found c-Myb 2KR to activate this promoter significantly stronger than wild-type cMyb did, confirming that synergy control is operating on the MYC promoter (Fig. S2) . The C-terminal regulatory domain in p53 harbours a SRAF.
The p53 transcription factor has an N-terminal TAD and a C-terminal regulatory domain (CRD) in which p53 is sumoylated at Lys386 (17, 18) . Using the Gal4p tethering assay we compared CRD wild-type and the sumoylation deficient K386R mutant. Interestingly, and as seen for c-Myb NRD and Sp3 ID, wild-type p53 CRD had a weak repressive effect, while the KR-version was activating (Fig. S3) , suggesting the presence of a SRAF in p53. Given that p53 tetramerizes on its natural promoters, the total contribution from four active CRDs in combination with four TADs is likely to result in an appreciable activation. The activated SRAF in c-Myb is p300 responsive.
The central TAD in c-Myb is known to bind p300 (19) (20) (21) , and it is believed that much of its transactivation function is mediated through this recruitment. To further analyze the SRAF in c-Myb NRD, we examined whether the NRD-2KR is co-activated by p300. When GBD-TAD, GBD-NRD (SRAF OFF) and GBD-NRD-2KR (SRAF ON) were co-transfected with p300, the classical central TAD was activated by p300 (Fig. S4A, right panel) , as earlier reported. In contrast GBD-NRD seemed to be unresponsive to p300. However, GBD-NRD-2KR (SRAF ON) was clearly p300-responsive (Fig. S4A, left panel, or RLU-plot Fig. S4B, right panel) .
This opens the possibility that the two activation functions in c-Myb cooperate in recruiting p300. Still, when we examined the interaction between p300 and the two AFs, only the classical TAD was able to pull-down full-length p300 from a COS-1 lysate (Fig S4C) . This implies that if c-Myb NRD participates in p300 recruitment, the interaction is most probably indirect.
A. B. expressing p300, and lysates were incubated with comparable amounts of recombinant GST, GST-TAD, GST-NRD, GST-NRD 2KR, and GST-NRD-SUMO1. The bound proteins were analyzed by SDS-PAGE and immunoblot analysis was performed using anti-p300 antibodies. 5% of the input (total cell extract) used for the pull-down was loaded as reference.
B.
C.
